To see what’s new in the women’s health market, it might be necessary to take a look back. The return of the IUD is just one comeback shaping the future of a field that has never been a stranger to controversy. Noah Pines reports on the latest developments in this space
Gilead’s curative but high-priced hepatitis C pill Sovaldi stirred payer frustration after its launch smashed sales records. Now firms from biotech to big pharma are gunning for their share of the HCV business. Will cost competition come to this space and allow these would-be rivals to chip away at Gilead’s dominance? Noah Pines reports from ringside
With generics firms taking aim at high-flying blockbusters, Big Pharma stalwarts in the asthma and COPD market are pinning their hopes for the future on a flurry of innovative biotech-developed assets. Noah Pines charts the rarefied air of the respiratory space
“New and improved” has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally better products is coming out. Noah Pines reviews the significant rare-disease market trends
Despite having the brightest data set of all the oral anticoagulants, the newest one is off to a rocky start. DTC advertising and medical education are under way, but it may take more to revive this launch.
In MS, a crop of orals has joined the older established therapies, yielding new options—and fierce competition. One thing they can all agree on: there’s been a transformation of the treatment landscape in just the last three years. Noah Pines reports
While public health agencies see eye-to-eye with industry on the need to inoculate, vaccination rates among some patient groups remain stubbornly low. Noah Pines on what this means for drug makers, and other areas where industry is rolling up its collective sleeves in an effort to get patients to roll up theirs
Companies in this space are expanding beyond reproductive health into areas like menopause and osteoporosis. To succeed, they’ll need to re-energize their physician and patient base. Noah Pines reports